Press releases
- Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
- Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
- Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
- Insulet to Present at the Jefferies Global Healthcare Conference
- Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
- Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
More ▼
Key statistics
On Tuesday, Insulet Corp (GOV:DUS) closed at 182.65, 51.77% above the 52 week low of 120.35 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 183.85 |
---|---|
High | 183.85 |
Low | 181.70 |
Bid | -- |
Offer | -- |
Previous close | 182.65 |
Average volume | 20.10 |
---|---|
Shares outstanding | 70.04m |
Free float | 69.80m |
P/E (TTM) | 61.24 |
Market cap | 13.78bn USD |
EPS (TTM) | 3.21 USD |
Data delayed at least 15 minutes, as of Jun 18 2024 18:30 BST.
More ▼